This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
No medical institute worthy of the name exists which has not been intrigued by the possibilities of research with the drug sulfanilamide or its derivatives. In fact, not since the epoch-making discovery of Ehrlich has a new chemotherapeutic agent received such universal scientific recognition as sulfanilamide. Dr. Konrad Birkhaug in his lecture delivered at the annual meeting of the Christian Michelsen Institute, Bergen (March 14, 1939), reviews much of the work which has already been covered in the enormous medical archives of the past three years. In his lecture he reviews the chemistry of the various compounds. He states: "Happily, this cumbersome chemical name has been abbreviated by the Council on Pharmacy and Chemistry of the American Medical Association to sulfanilamide." In his lecture he pays particular attention to the work on sulfanilamide as outlined by Marshall, Emerson and Cutting and discusses thoroughly the dosage and chemotherapeutic range of the
Sulphonamide Treatment of Experimental Tuberculosis in Guinea Pigs. JAMA. 1939;113(20):1835. doi:10.1001/jama.1939.02800450057032
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: